Core Insights - Aclarion, Inc. has secured nearly $20 million in gross proceeds to fully fund its pivotal CLARITY trial, which aims to validate the effectiveness of Nociscan in improving surgical outcomes for chronic low back pain patients [1][2] - The CLARITY trial is a prospective, randomized, multicenter study enrolling 300 patients, led by Dr. Nicholas Theodore from Johns Hopkins, and builds on existing peer-reviewed data supporting Nociscan's potential [2][3] - Nociscan is positioned as a groundbreaking solution in the chronic low back pain market, utilizing Magnetic Resonance Spectroscopy (MRS) and augmented intelligence to differentiate between painful and nonpainful discs [3][5] Funding and Trial Details - The funding secured since January 1, 2025, ensures the completion of the CLARITY trial, which is critical for potentially unlocking broader payer coverage for Nociscan [2] - The trial aims to demonstrate Nociscan's clinical and economic value in spine surgery, with a focus on matching surgical interventions to specific discs identified as pain sources [2][3] Market Context - Chronic low back pain affects approximately 266 million people globally, highlighting the significant healthcare challenge and the potential market for Aclarion's Nociscan solution [3] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively assist physicians in identifying the source of low back pain, achieving a reported 97% surgical success rate at one year follow-up when treating identified pain-positive discs [3][5]
Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded